Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -8.31% | -9.23% | -0.63% | -2.87% | -4.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.31% | -9.23% | -0.63% | -2.87% | -4.18% |
| Cost of Revenue | -20.86% | -21.00% | -9.06% | -8.54% | -6.59% |
| Gross Profit | 0.55% | -0.66% | 5.52% | 1.32% | -2.40% |
| SG&A Expenses | 6.26% | 14.74% | 14.92% | 3.88% | -3.76% |
| Depreciation & Amortization | 35.61% | 56.91% | 53.77% | 42.01% | 23.63% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.02% | 1.10% | 6.71% | 0.74% | -3.85% |
| Operating Income | -51.05% | -74.14% | -53.26% | -31.25% | -6.77% |
| Income Before Tax | -257.92% | -100.78% | -72.99% | -86.19% | 1,258.49% |
| Income Tax Expenses | 114.87% | 166.22% | 103.59% | -2,270.00% | -352.19% |
| Earnings from Continuing Operations | -206.54% | -107.64% | -83.40% | -26.19% | 1,150.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -206.54% | -107.64% | -83.40% | -26.19% | 1,150.00% |
| EBIT | -51.05% | -74.14% | -53.26% | -31.25% | -6.77% |
| EBITDA | -18.72% | -36.22% | -19.81% | -7.95% | 2.69% |
| EPS Basic | -177.59% | -106.88% | -81.62% | -11.52% | 882.79% |
| Normalized Basic EPS | -92.82% | -120.43% | -117.36% | -75.00% | 46.34% |
| EPS Diluted | -177.96% | -107.02% | -81.80% | -12.08% | 761.81% |
| Normalized Diluted EPS | -92.67% | -120.59% | -117.53% | -76.91% | 43.34% |
| Average Basic Shares Outstanding | 25.15% | 28.99% | 21.70% | 18.78% | 15.67% |
| Average Diluted Shares Outstanding | 24.13% | 27.88% | 20.65% | 19.69% | 16.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |